CCCC Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . C4 Therapeutics
CCCC Stock  USD 4.55  0.36  8.59%   
C4 Therapeutics financial statements provide useful quarterly and yearly information to potential C4 Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on C4 Therapeutics financial statements helps investors assess C4 Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting C4 Therapeutics' valuation are summarized below:
Gross Profit
-86.7 M
Market Capitalization
321.2 M
Enterprise Value Revenue
3.9395
Revenue
33.7 M
Earnings Share
(1.71)
We have found one hundred twenty available fundamental measures for C4 Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. Investors should ensure to validate all of C4 Therapeutics' latest performance against the performance from 2010 to 2024 to make sure the company is sustainable this quarter and beyond. As of November 30, 2024, Market Cap is expected to decline to about 266.4 M. In addition to that, Enterprise Value is expected to decline to about 213.6 M

C4 Therapeutics Total Revenue

31.46 Million

Check C4 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among C4 Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 1.3 M, Net Interest Income of 6.9 M or Interest Income of 9 M, as well as many indicators such as Price To Sales Ratio of 12.84, Dividend Yield of 0.0 or PTB Ratio of 1.2. CCCC financial statements analysis is a perfect complement when working with C4 Therapeutics Valuation or Volatility modules.
  
Check out the analysis of C4 Therapeutics Correlation against competitors.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

C4 Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets362.8 M376.5 M234.2 M
Slightly volatile
Short and Long Term Debt Total46.2 M71 M27.6 M
Slightly volatile
Other Current Liabilities11.2 M15.4 M6.4 M
Slightly volatile
Total Current Liabilities44 M42.8 M31.7 M
Slightly volatile
Other Liabilities14.4 M15.2 M59.7 M
Slightly volatile
Property Plant And Equipment Net43.9 M71.1 M29.8 M
Slightly volatile
Current Deferred Revenue27.2 M15.5 M21.9 M
Slightly volatile
Accounts Payable2.6 M1.4 M2.1 M
Slightly volatile
Cash99.2 M126.6 M62 M
Slightly volatile
Non Current Assets Total90.4 M105.3 M51.2 M
Slightly volatile
Non Currrent Assets Other4.1 M6.2 M3.2 M
Slightly volatile
Other Assets3.6 M5.5 M3.1 M
Slightly volatile
Cash And Short Term Investments256.4 M253.7 M129.7 M
Slightly volatile
Net Receivables15.3 M11.8 M54.8 M
Slightly volatile
Common Stock Shares Outstanding45 M49.6 M27.2 M
Slightly volatile
Liabilities And Stockholders Equity362.8 M376.5 M234.2 M
Slightly volatile
Non Current Liabilities Total96.7 M87.6 M162.7 M
Slightly volatile
Capital Lease Obligations40.3 M71 M25.1 M
Slightly volatile
Other Current Assets9 M5.7 M4.3 M
Slightly volatile
Total Liabilities128.7 M130.3 M193.6 M
Slightly volatile
Property Plant And Equipment Gross48.1 M78.9 M31.6 M
Slightly volatile
Total Current Assets272.4 M271.2 M183.1 M
Slightly volatile
Net Working Capital228.4 M228.4 M151.4 M
Slightly volatile
Short Term Debt5.2 M10.4 M2.6 M
Slightly volatile
Common Stock4 K6 K2.3 K
Slightly volatile
Property Plant Equipment10.6 M6.7 M16.4 M
Slightly volatile
Long Term Debt8 M8.3 M9.8 M
Slightly volatile
Common Stock Total Equity5.1 K5.8 K4.3 K
Slightly volatile
Short Term Investments159.3 M127.1 M190.4 M
Very volatile
Long Term Debt Total8 M8.3 M9.8 M
Slightly volatile
Capital Surpluse664.4 M792.6 M527.7 M
Slightly volatile
Deferred Long Term Liabilities31.2 M21.9 M46.1 M
Slightly volatile
Non Current Liabilities Other106.1 M101 M30.4 M
Slightly volatile
Short and Long Term Debt1.8 M2.1 M2.2 M
Slightly volatile

C4 Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income9 M8.6 M2 M
Slightly volatile
Depreciation And Amortization4.4 M7.7 M2.6 M
Slightly volatile
Selling General Administrative27.4 M42.1 M15.6 M
Slightly volatile
Total Revenue31.5 M20.8 M23.9 M
Slightly volatile
Other Operating Expenses116.3 M159.8 M69.1 M
Slightly volatile
Research Development89 M117.7 M53.5 M
Slightly volatile
Total Operating Expenses116.3 M159.8 M69.1 M
Slightly volatile
Reconciled Depreciation1.8 M2 M1.4 M
Slightly volatile
Cost Of Revenue123.6 M117.7 M53.7 M
Slightly volatile
Selling And Marketing Expenses6.2 M7 M7.6 M
Slightly volatile

C4 Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings10 M11.2 M12.2 M
Slightly volatile
Stock Based Compensation15.5 M27.2 M7 M
Slightly volatile
Begin Period Cash Flow31.4 M33 M40.9 M
Slightly volatile
Depreciation1.7 M1.9 M1.4 M
Slightly volatile
Other Non Cash Items3.3 M3.5 M2.7 M
Slightly volatile
Capital Expenditures2.4 M1.7 M2.5 M
Pretty Stable
Total Cash From Financing Activities43.2 M45.5 M41.9 M
Slightly volatile
End Period Cash Flow102.4 M130 M64.8 M
Slightly volatile
Change To Netincome36.2 M34.5 M9.4 M
Slightly volatile
Dividends Paid9.6 M10.8 M11.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.8413.512722.4949
Very volatile
Days Sales Outstanding3722071 K
Slightly volatile
Stock Based Compensation To Revenue1.381.31220.3052
Slightly volatile
Capex To Depreciation1.120.90851.7615
Slightly volatile
EV To Sales10.2910.833220.9861
Very volatile
Payables Turnover85.4781.401127.9632
Slightly volatile
Sales General And Administrative To Revenue2.132.02740.6971
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue5.955.67092.3585
Slightly volatile
Capex To Revenue0.06780.08230.1125
Slightly volatile
Cash Per Share4.095.11043.6271
Slightly volatile
Days Payables Outstanding4.264.48455.4404
Pretty Stable
Current Ratio4.786.34125.4613
Pretty Stable
Receivables Turnover1.671.75913.1063
Slightly volatile
Graham Number11.7217.255212.6963
Slightly volatile
Capex Per Share0.03270.03440.126
Slightly volatile
Revenue Per Share0.40.41811.0335
Slightly volatile
Interest Debt Per Share1.531.45750.5401
Slightly volatile
Debt To Assets0.20.18850.1154
Pretty Stable
Days Of Payables Outstanding4.264.48455.4404
Pretty Stable
Ebt Per Ebit1.090.94380.9813
Slightly volatile
Quick Ratio4.976.34125.5652
Slightly volatile
Net Income Per E B T1.111.00981.0243
Pretty Stable
Cash Ratio2.462.96011.8703
Slightly volatile
Days Of Sales Outstanding3722071 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.0161.1089
Slightly volatile
Fixed Asset Turnover0.280.2920.931
Pretty Stable
Debt Ratio0.20.18850.1154
Pretty Stable
Price Sales Ratio12.8413.512722.4949
Very volatile
Asset Turnover0.110.05510.1187
Slightly volatile

C4 Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap266.4 M280.5 M548.8 M
Pretty Stable
Enterprise Value213.6 M224.9 M514.4 M
Pretty Stable

CCCC Fundamental Market Drivers

Cash And Short Term Investments253.7 M

CCCC Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About C4 Therapeutics Financial Statements

C4 Therapeutics stakeholders use historical fundamental indicators, such as C4 Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although C4 Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in C4 Therapeutics' assets and liabilities are reflected in the revenues and expenses on C4 Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in C4 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue15.5 M27.2 M
Total Revenue20.8 M31.5 M
Cost Of Revenue117.7 M123.6 M
Stock Based Compensation To Revenue 1.31  1.38 
Sales General And Administrative To Revenue 2.03  2.13 
Research And Ddevelopement To Revenue 5.67  5.95 
Capex To Revenue 0.08  0.07 
Revenue Per Share 0.42  0.40 
Ebit Per Revenue(6.70)(6.36)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:
How To Invest In CCCC
Details
Is CCCC Stock a good investment?
Details
What is C4 Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of C4 Therapeutics Correlation against competitors.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.71)
Revenue Per Share
0.522
Quarterly Revenue Growth
0.387
Return On Assets
(0.21)
Return On Equity
(0.46)
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY